Ribolia Biopharma Secures Over RMB 200 Million in Series E Financing to Advance Global siRNA Drug Pipeline

Ribo Life Science is a global leader specializing in the research and development of small nucleic acid (siRNA) drugs. Ribo Life Science aligns with the innovative frontier of international small nucleic acid technology, committing to the iterative research and development of small nucleic acid chemical modification and drug delivery technologies. It has established an independent and controllable small nucleic acid drug R&D platform that integrates the entire technical chain, supporting various stages of small nucleic acid drug research from early development to industrialization. The company has built a rich product pipeline covering cardiovascular, metabolic, liver, kidney, and other therapeutic areas, including its self-developed liver-targeting RiboGalSTAR.^TMDelivery technology has advanced multiple products to Phase II clinical trials, with efficacy and safety well-validated clinically. The company adheres to a differentiated approach in target and product development, supported by an international innovative R&D team. It conducts research, development, and commercialization globally, striving to bring new therapeutic options to patients as soon as possible. Headquartered in Kunshan, Jiangsu, the company has research centers in Beijing and Mölndal, Sweden. For more information, please visit www.ribolia.com.

Mingxin Capital was founded in 2006 as an international private equity fund focused on investing in high-tech companies at their growth stage. Mingxin Capital is committed to pooling global resources to help Chinese biopharmaceutical companies expand into international markets and become world-leading enterprises.

Kunshan High-Tech Venture Capital Co., Ltd. (Kunshan High-Tech VC) was established in 2012 as a state-owned venture capital platform wholly owned by Kunshan High-Tech Group Co., Ltd. With a registered capital of 300 million yuan, it adopts a dual-driven model of direct investment and fund investment, focusing on equity investment and industrial incubation. It emphasizes sectors such as information technology, intelligent manufacturing, biomedicine, new energy, and new materials, continuously investing in "new economy" enterprises. Kunshan High-Tech VC is one of the company's existing shareholders.

Kunshan Guoke Venture Capital Co., Ltd. (Kunshan Guoke Venture Capital) was established in 2001 with a registered capital of 725 million RMB. It is a venture capital company under Kunshan Entrepreneurship Holding Co., Ltd. Its business scope includes venture capital investment and management of venture capital funds for high-tech enterprises and technology innovation companies. The investment areas cover electronics, metal materials, biomedicine, chip design, high-end equipment, rapid prototyping manufacturing, optoelectronic industry, and many other fields, laying a solid foundation for the development of related industries in Kunshan City. Kunshan Guoke Venture Capital is one of the existing shareholders of the company.

Qin Chuang Investment was founded in 2015, with investment areas covering healthcare, new-generation information technology, high-end manufacturing, and more. The companies it has invested in include YouNuoJin Bio, AijieBola, XiPu Sunshine, AnCheng Computer, etc. ChouQin Venture Capital participated in the company's previous round of financing.

Panlin Capital is a VC with both professionalism and influence in the two fields of healthcare and technology. Established in 2010, Panlin Capital adheres to the investment theme of "Technology creates the future, innovation leads upgrading," focusing on the two fields of healthcare and technology to uncover angel to A-round projects, and is committed to "finding entrepreneurs among scientists and nurturing innovators among entrepreneurs." In the healthcare sector, Panlin invests in innovative drug development companies targeting prevention, diagnosis, and treatment of major diseases with unmet clinical needs, as well as innovative medical device development companies, while exploring derivative investment opportunities in life sciences and biotechnology. In the technology sector, Panlin invests in To B enterprises (enterprise services and data intelligent equipment) that meet the demand for cost reduction, efficiency enhancement, and quality improvement on the B-end, and hard tech companies (equipment and key components) that ensure key technologies are independently controllable. Prior to this round, Panlin Capital has led or participated in a total of five rounds of financing for the company, making it the investment institution with the most investment rounds.

Zhuhai SoftBank Xinchuang, as the fund manager of Shenzhen Xinchuang Medical Integration, is a Renminbi venture capital and private equity fund management company dedicated to investing in outstanding high-growth, high-tech enterprises in the Greater China region. The team originates from the healthcare investment team of SoftBank China Capital (SBCVC) and has successfully invested in a series of excellent companies such as DiAn Diagnostics, BGI, Pulnovo Medical, and Edan Instruments. Investment areas mainly cover healthcare, including cell and gene therapy, AI and digital healthcare, synthetic biology, brain science, and more.

Langma Peak Venture Capital was founded in September 2007, with offices in Beijing, Shenzhen, and Shanghai. Its investment scope covers the globe, primarily focusing on high-tech industries such as healthcare, semiconductors, artificial intelligence, advanced manufacturing, automotive transportation, and new energy. To date, it has invested in 128 companies, with 38 listed companies and more than ten either in the process of review or awaiting listing approval. Over the past 18 years since its establishment, Langma Peak Venture Capital has consistently been committed to promoting the rapid development of innovative enterprises. With precise investment insights and professional strategies, it has injected capital and resources into numerous innovative companies, helping them stand out in the market and achieve rapid growth. Meanwhile, Langma Peak Venture Capital issues venture capital funds, allowing investors to share in the growth dividends of high-tech enterprises, earning the trust of investors and widespread acclaim from the business community.